GENMAB

Genmab’s EPCORE DLBCL‑1 results show improved PFS but no OS win, raising questions on pricing, reimbursement and the bispecific antibody market. Read the full analysis.

Genmab’s early 2026 trial of epcoritamab shows PFS, CR, and DOR gains in DLBCL, yet no OS benefit, prompting a Jyske Bank price hike and investor reassessment.

Genmab partners with Anthropic’s Claude AI to speed antibody R&D, automate data analysis and regulatory drafting, aiming to accelerate oncology drug development.

Genmab partners with Anthropic to embed AI into antibody drug development, cutting data handling time, boosting safety insights, and speeding regulatory approval.

Genmab A/S cuts acasunlimab to focus on high‑potential oncology assets, boosting portfolio value and payer alignment for future growth.

Genmab’s €400 m acquisition of Merus adds petosemtamab, a Breakthrough Therapy bispecific antibody for head‑and‑neck cancer, boosting its oncology pipeline and potential revenue.

Genmab’s epcoritamab shows 70‑80% response in follicular lymphoma, with a US NPV of $1.1 B—boosting its value, pricing strategy, and M&A appeal.

Genmab’s Phase 3 EPCORE FL‑1 data show epcoritamab boosts response rates by 20% in relapsed follicular lymphoma, hinting at high market value and regulatory upside.

Genmab’s subcutaneous bispecific epcoritamab shows >70 % response and durable survival in first‑line diffuse large B‑cell and follicular lymphoma, offering a safer, fixed‑duration alternative to anthracyclines.

Genmab A/S, a Danish biotech company, is poised for commercial success with its bispecific antibody Rina-S, which has shown impressive early-stage clinical results in advanced endometrial cancer and has received Breakthrough Therapy Designation from…